Data derived from 18F-FDG PET, Amyloid PET, and Tau PET, which provided relevant insights into cerebral metabolism and pathological protein deposition, could be used for the early diagnosis of AD in high-risk subjects. This evidence concerns the gene MAPT and Alzheimer disease.